Deal Overview

Novartis announced on ⁢Tuesday, ⁤May 21, 2024, its agreement to acquire Tourmaline Bio for ⁢approximately $1.4 billion.the acquisition aims to strengthen Novartis’s portfolio in cardiovascular disease, focusing⁤ on the ⁢promising drug candidate pacibekitug. Novartis’s official press release details the terms of the ‍agreement.

The⁣ deal values ‍Tourmaline Bio at $48 per share, representing a 59% premium over the company’s closing ⁣price of $30.28 on Monday,May 20,2024. Yahoo⁣ Finance provides historical ⁤stock data for⁤ Tourmaline Bio.

Pacibekitug:⁢ The Key Asset

The primary driver of the acquisition is pacibekitug,an investigational antibody targeting ‍fibromodulin. This drug is currently⁢ in‍ clinical trials for atherosclerotic cardiovascular disease (ASCVD) and othre heart conditions. ⁣ Tourmaline Bio’s pipeline page outlines the⁢ development status of pacibekitug.

Recent mid-stage trial ⁤data, presented in May 2024, demonstrated that pacibekitug significantly reduced levels of lipoprotein(a) [Lp(a)],‍ a genetically elevated cholesterol-like particle ⁢linked to increased⁣ risk of heart disease. STAT News reported ⁣that the drug ‍achieved ⁣reductions of up to 95% in Lp(a) levels.

ASCVD ⁢is a leading cause of death ⁢globally.According to the Centers for Disease Control and⁤ Prevention (CDC), about 695,000 people in the United States died from‍ heart disease ‍in 2021.

Financial Details and Timeline

The $1.4 billion deal consists of ⁣an upfront payment of $48 per ⁤share in cash. Novartis expects the acquisition to close in the second quarter of 2024, subject to customary closing conditions, including regulatory approvals. A Form 8-K filing wiht the Securities and Exchange Commission provides further‍ details on the transaction.

Implications for Novartis and the Cardiovascular Landscape

This acquisition aligns with Novartis’s strategic focus⁢ on innovative medicines and its commitment to expanding